Metraipolis › archive › dc_d6f613e95b5a
Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42291898
- DOI
- 10.7759/cureus.108823
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T08:04:54.468Z
- SHA-256 of the archived text
705025436ae4ca37d79b82e5a179a8fd196819367b272cd5816e5e1cf6d0f893- Stable URL of this page
https://metraipolis.com/documento/dc_d6f613e95b5a
How to cite
Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898 — Europe PMC (en), https://europepmc.org/article/MED/42291898 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d6f613e95b5a (Metraipolis archive dc_d6f613e95b5a, sha256 705025436ae4ca37d79b82e5a179a8fd196819367b272cd5816e5e1cf6d0f893)
BibTeX
@misc{dcd6f613e95b5a,
title = {Single-Institution Outcomes of Neoadjuvant Gemcitabine and Nab-Paclitaxel Combination in Borderline Resectable Pancreatic Adenocarcinoma: A Three-Year… — Europe PMC PMID:42291898},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42291898},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d6f613e95b5a; sha256 705025436ae4ca37d79b82e5a179a8fd196819367b272cd5816e5e1cf6d0f893},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42291898. Agents can read the archived copy with the MCP tool read_document.